Vesselon

Executive Summary

Vesselon is a San Diego-based drug delivery company pioneering the use of FDA-approved lipid microspheres and self-assembling liposomes to create patentable co-formulations. These formulations are designed to enhance the permeability of targeted tissues, significantly improving the efficacy of co-administered therapeutics. The company's proprietary platform has already achieved regulatory approval, positioning it to generate revenue and pursue further clinical applications. Vesselon's technology addresses a critical challenge in drug delivery—overcoming biological barriers to achieve high local drug concentrations while minimizing systemic toxicity. With a focus on repurposing existing drugs through advanced formulation, Vesselon offers a capital-efficient path to market for enhanced therapeutic outcomes. Looking ahead, Vesselon is well-positioned to expand its platform into new therapeutic areas, including oncology and central nervous system disorders. The company's strategy involves securing strategic partnerships with pharmaceutical firms to leverage its delivery technology across multiple drug candidates. Additionally, ongoing clinical studies are expected to yield data supporting the platform's broad applicability. Vesselon's management has demonstrated execution capability through its initial FDA approval, and the company is likely to pursue additional approvals for co-formulations with high unmet medical need. Given its validated platform, strong intellectual property, and potential for partnership-driven growth, Vesselon represents an attractive opportunity in the drug delivery space.

Upcoming Catalysts (preview)

• Q4 2026Strategic partnership with a major pharma company for co-development of a new co-formulation65% success
• Q1 2027Publication of Phase 2 clinical data demonstrating enhanced efficacy of a lead co-formulation75% success
• Q2 2027FDA approval for a second co-formulation in a new therapeutic indication55% success